PMID: 9184716Jun 1, 1997Paper

Riluzole: a new agent for amyotrophic lateral sclerosis

The Annals of Pharmacotherapy
M L Wagner, B E Landis

Abstract

To provide a comprehensive review of riluzole, including its mechanism of action, pharmacokinetics, adverse drug reactions, drug interactions, efficacy, and administration. A brief review of amyotrophic lateral sclerosis (ALS) is also included. A computerized search of the MEDLINE database in May 1996 was used to identify publications regarding ALS, riluzole, and metabolism by CYP1A2. Manufacturer's information on riluzole was used when there was no primary literature. Riluzole is approximately 90% absorbed following an oral dose. Its bioavailability is 60%. Peak concentrations occur within 1-1.5 hours of administration. Riluzole extensively binds to lipoproteins and albumin. This agent primarily undergoes CYP1A2 hydroxylation and glucuronidation, after which it is eliminated by the kidneys. Clearance is reduced in native Japanese healthy subjects and may be reduced in patients with hepatic impairment. Two trials with a total of 1114 patients addressed the efficacy of riluzole in ALS. Riluzole extended the time to tracheostomy or death, and the effect was greatest with dosages of 100 mg/d or greater. No effect on patients' symptoms or global assessment was detected at 18 or 21 months. Several flaws in these trials have led to q...Continue Reading

References

Oct 1, 1978·Archives of Neurology·A D Rosen
May 28, 1992·The New England Journal of Medicine·J D RothsteinR W Kuncl
May 28, 1992·The New England Journal of Medicine·D W Choi
Dec 1, 1991·Pflügers Archiv : European journal of physiology·E Benoit, D Escande
Jan 1, 1991·Mayo Clinic Proceedings·D B Williams, A J Windebank
Dec 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·T M LiM Swash
Jun 1, 1995·Clinical Pharmacokinetics·S MaddenB K Park
Mar 3, 1994·The New England Journal of Medicine·S A Lipton, P A Rosenberg
Jul 28, 1994·The New England Journal of Medicine·A Samuels
Jul 28, 1994·The New England Journal of Medicine·K D McRae
Dec 1, 1993·Clinical Pharmacokinetics·J G GillumR E Polk
Sep 1, 1993·Journal of the Neurological Sciences·S H AppelE Stefani
Mar 3, 1994·The New England Journal of Medicine·G BensimonV Meininger
Mar 3, 1994·The New England Journal of Medicine·L P Rowland
Jul 1, 1993·Neurology·S P RingelF Ziter
Mar 4, 1993·Nature·J O McNamara, I Fridovich
Apr 1, 1993·Journal of Neurochemistry·A Frandsen, A Schousboe
Jan 1, 1995·International Journal of Psychiatry in Medicine·W W Shen
Oct 1, 1996·Neurology·E J Kasarskis, H E Neville
Oct 1, 1996·Neurology·L C HopkinsT F Pianta

❮ Previous
Next ❯

Citations

Jun 18, 2002·Acta Neurologica Scandinavica·I Niebroj-DoboszH Kwieciński
May 12, 2009·Alcoholism, Clinical and Experimental Research·Joyce BesheerClyde W Hodge
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Jan 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·O ChassanyJ F Bergmann
Jul 28, 2004·Journal of Neurophysiology·Efstratios K KosmidisJean-François Vibert
Nov 26, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jared R AuclairJeffrey N Agar
Oct 13, 2000·The European Journal of Neuroscience·A Urbani, O Belluzzi
Aug 5, 2000·The Annals of Pharmacotherapy·W A NorthJ R Sporn
Aug 30, 2008·Expert Opinion on Drug Metabolism & Toxicology·Carlos A Zarate, Husseini K Manji
Jan 30, 2013·The Journal of Pharmacy and Pharmacology·Punna Rao RaviUpendra Reddy Kora
Aug 28, 2020·Neurodegenerative Disease Management·Yuji Saitoh, Yuji Takahashi
May 12, 2004·Neurology·Gabriel Weber, Haim Bitterman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Related Papers

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
T LengletMitotarget study group
The Cochrane Database of Systematic Reviews
R G MillerD H Moore
The Cochrane Database of Systematic Reviews
R G MillerD H Moore
© 2021 Meta ULC. All rights reserved